448 related articles for article (PubMed ID: 31378655)
1. Neoadjuvant Chemotherapy With mFOLFOXIRI Without Routine Use of Radiotherapy for Locally Advanced Rectal Cancer.
Zhang J; Huang M; Cai Y; Wang L; Xiao J; Lan P; Hu H; Wu X; Ling J; Peng J; Chen D; Kang L; Zhang Y; Ren D; Wang H; Chen S; Lin F; Zheng J; Zhou Z; Wang J; Deng Y
Clin Colorectal Cancer; 2019 Dec; 18(4):238-244. PubMed ID: 31378655
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301).
Miwa K; Oki E; Enomoto M; Ihara K; Ando K; Fujita F; Tominaga M; Mori S; Nakayama G; Shimokawa M; Saeki H; Baba H; Mori M; Akagi Y
BMC Cancer; 2021 Jan; 21(1):23. PubMed ID: 33402130
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer to transform effectively EMVI and MRF from positive to negative: results of a long-term single center phase 2 clinical trial.
Zhang W; Zhou H; Jiang J; Zhu Y; Zou S; Jiang L; Tang Y; Liang J; Sun Y; Jiang Z; Qu W; Li Y; Zhou A
BMC Cancer; 2023 Jun; 23(1):592. PubMed ID: 37370032
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
Schrag D; Weiser MR; Goodman KA; Gonen M; Hollywood E; Cercek A; Reidy-Lagunes DL; Gollub MJ; Shia J; Guillem JG; Temple LK; Paty PB; Saltz LB
J Clin Oncol; 2014 Feb; 32(6):513-8. PubMed ID: 24419115
[TBL] [Abstract][Full Text] [Related]
5. mFOLFOXIRI versus mFOLFOX6 as neoadjuvant chemotherapy in locally advanced rectal cancer: A Propensity Score Matching Analysis.
Ding M; Zhang J; Hu H; Cai Y; Ling J; Wu Z; Xie X; Li J; Li W; Deng Y
Clin Colorectal Cancer; 2022 Mar; 21(1):e12-e20. PubMed ID: 34963563
[TBL] [Abstract][Full Text] [Related]
6. Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma.
Shamseddine A; Zeidan YH; Kreidieh M; Khalifeh I; Turfa R; Kattan J; Mukherji D; Temraz S; Alqasem K; Amarin R; Al Awabdeh T; Deeba S; Jamali F; Mohamad I; Elkhaldi M; Daoud F; Al Masri M; Dabous A; Hushki A; Jaber O; Khoury C; El Husseini Z; Charafeddine M; Al Darazi M; Geara F
BMC Cancer; 2020 Sep; 20(1):831. PubMed ID: 32873251
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study.
Borg C; Mantion G; Boudghène F; Mornex F; Ghiringhelli F; Adenis A; Azria D; Balosso J; Ben Abdelghani M; Bachet JB; Vendrely V; François Y; Conroy T; Rio E; Roullet B; Spaëth D; Quero L; Lakkis Z; Coudert M; Ionescu-Goga M; Tanang A; André T
Clin Colorectal Cancer; 2019 Sep; 18(3):200-208.e1. PubMed ID: 31311761
[TBL] [Abstract][Full Text] [Related]
8. Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial.
Deng Y; Chi P; Lan P; Wang L; Chen W; Cui L; Chen D; Cao J; Wei H; Peng X; Huang Z; Cai G; Zhao R; Huang Z; Xu L; Zhou H; Wei Y; Zhang H; Zheng J; Huang Y; Zhou Z; Cai Y; Kang L; Huang M; Peng J; Ren D; Wang J
J Clin Oncol; 2016 Sep; 34(27):3300-7. PubMed ID: 27480145
[TBL] [Abstract][Full Text] [Related]
9. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial.
Lee JB; Kim HS; Jung I; Shin SJ; Beom SH; Chang JS; Koom WS; Kim TI; Hur H; Min BS; Kim NK; Park S; Jeong SY; Baek JH; Kim SH; Lim JS; Lee KY; Ahn JB
Trials; 2020 Apr; 21(1):320. PubMed ID: 32264919
[TBL] [Abstract][Full Text] [Related]
10. NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial).
Brouquet A; Bachet JB; Huguet F; Karoui M; Artru P; Sabbagh C; Lefèvre JH; Vernerey D; Mariette C; Vicaut E; Benoist S;
BMC Cancer; 2020 May; 20(1):485. PubMed ID: 32471382
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant-intensified treatment for rectal cancer: time to change?
Musio D; De Felice F; Bulzonetti N; Guarnaccia R; Caiazzo R; Bangrazi C; Raffetto N; Tombolini V
World J Gastroenterol; 2013 May; 19(20):3052-61. PubMed ID: 23716984
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
13. Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer.
Cercek A; Roxburgh CSD; Strombom P; Smith JJ; Temple LKF; Nash GM; Guillem JG; Paty PB; Yaeger R; Stadler ZK; Seier K; Gonen M; Segal NH; Reidy DL; Varghese A; Shia J; Vakiani E; Wu AJ; Crane CH; Gollub MJ; Garcia-Aguilar J; Saltz LB; Weiser MR
JAMA Oncol; 2018 Jun; 4(6):e180071. PubMed ID: 29566109
[TBL] [Abstract][Full Text] [Related]
14. Phase II Trial of Neoadjuvant Chemotherapy, Chemoradiotherapy, and Laparoscopic Surgery with Selective Lateral Node Dissection for Poor-Risk Low Rectal Cancer.
Konishi T; Shinozaki E; Murofushi K; Taguchi S; Fukunaga Y; Nagayama S; Fujimoto Y; Akiyoshi T; Nagasaki T; Suenaga M; Chino A; Kawachi H; Yamamoto N; Ishikawa Y; Oguchi M; Ishizuka N; Ueno M; Yamaguchi K
Ann Surg Oncol; 2019 Aug; 26(8):2507-2513. PubMed ID: 30963400
[TBL] [Abstract][Full Text] [Related]
15. Neo-adjuvant chemotherapy alone for the locally advanced rectal cancer: a systematic review.
Manatakis DK; Gouvas N; Souglakos J; Xynos E
Int J Clin Oncol; 2020 Sep; 25(9):1570-1580. PubMed ID: 32666388
[TBL] [Abstract][Full Text] [Related]
16. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.
Shamseddine A; Zeidan YH; El Husseini Z; Kreidieh M; Al Darazi M; Turfa R; Kattan J; Khalifeh I; Mukherji D; Temraz S; Alqasem K; Amarin R; Al Awabdeh T; Deeba S; Jamali F; Mohamad I; Elkhaldi M; Daoud F; Al Masri M; Dabous A; Hushki A; Jaber O; Charafeddine M; Geara F
Radiat Oncol; 2020 Oct; 15(1):233. PubMed ID: 33028346
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial.
Gao YH; Lin JZ; An X; Luo JL; Cai MY; Cai PQ; Kong LH; Liu GC; Tang JH; Chen G; Pan ZZ; Ding PR
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1153-60. PubMed ID: 25442042
[TBL] [Abstract][Full Text] [Related]
19. Retrospective Comparison of mFOLFOXIRI With XELOX/SOX as Neoadjuvant Chemotherapy for Locally Advanced Rectal Cancer.
Kodama H; Terazawa T; Ishizuka Y; Yukami H; Aoki M; Miyamoto T; Yamaguchi T; Shimamoto F; Kii T; Goto M; Hamamoto H; Osumi W; Yamamoto M; Tanaka K; Okuda J; Uchiyama K; Higuchi K
In Vivo; 2021; 35(2):977-985. PubMed ID: 33622892
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum.
Glynne-Jones R; Hava N; Goh V; Bosompem S; Bridgewater J; Chau I; Gaya A; Wasan H; Moran B; Melcher L; MacDonald A; Osborne M; Beare S; Jitlal M; Lopes A; Hall M; West N; Quirke P; Wong WL; Harrison M;
BMC Cancer; 2015 Oct; 15():764. PubMed ID: 26493588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
